Alantra advises FLOTTE on the sale of sanotact to Avista Healthcare Partners and Damier

May 2026

Sell-side advisory

London / Frankfurt – Alantra has acted as exclusive M&A advisor to FLOTTE Beteiligungen GmbH (“FLOTTE”) on the signing of a definitive agreement for the sale of sanotact Group GmbH (“sanotact” or the “Company”), an established and innovative German vitamins, minerals, and supplements (“VMS”) platform, to Avista Healthcare Partners (“Avista”) and Damier Group (“Damier”). As part of the transaction, FLOTTE will make a significant reinvestment and continue to support the growth of the Company alongside the new shareholders.

Headquartered in Münster, Germany, sanotact specializes in the development, manufacturing, and commercialization of VMS products. The Company operates a diversified business model combining a scaled, full-service CDMO platform with capabilities across all major VMS dosage forms and a portfolio of branded VMS products, including sanotact®, an established German VMS brand. sanotact serves leading drugstore and distribution customers and has established a strong reputation as a trusted innovation partner, underpinned by its high-quality manufacturing and broad product capabilities across 80 international markets.

The transaction represents an important milestone in sanotact’s continued development. Avista brings deep experience in consumer healthcare across North America and Europe, while Damier contributes a strong track record of building and scaling consumer healthcare platforms. Together with FLOTTE’s continued support, the new shareholder group is well positioned to support sanotact’s next phase of growth, including further investment in innovation, international expansion, and strategic development.

Charles Lanceley, Managing Director at Alantra and Head of the VMS CDMO practice, said: “We are delighted to have secured an excellent partner for FLOTTE, with deep sector expertise, a proven track record, and a shared vision for growth. This is a standout transaction in the European VMS CDMO sector, which continues to attract strong interest from both financial sponsors and strategic consolidators, supported by compelling underlying market fundamentals. The transaction reinforces Alantra’s position as the No. 1 M&A advisor in the sector, having advised on 6 transactions across 5 countries over the past 18 months.“

Christopher Jobst, Managing Director at Alantra, added: “We are pleased to have supported FLOTTE on this transaction, which marks an exciting new chapter for sanotact alongside Avista and Damier.”

This transaction adds to Alantra’s strong momentum advising clients in the global VMS CDMO sector, with 13 deals across 10 countries since 2020. Recent transactions include advising CapMan on the sale of Pharmia to Labomar, Aminolabs Nutrition on the acquisition of Zoka Pharma, Venture Life Group plc on the sale of Biokosmes to Healthea Group, Perrigo on the sale of Richard Bittner to DCC HBI (now part of Ourvita), and Oakley Capital on the sale of Windstar Medical to Merz Lifecare.